Home > Neurology > ECTRIMS 2021 > COVID-19 > MS patients at risk of hampered immune response after vaccination

MS patients at risk of hampered immune response after vaccination

Presented By
Prof. Maria Pia Sormani, University of Genoa, Italy
Conference
ECTRIMS 2021
MS patients treated with ocrelizumab, rituximab, or fingolimod showed a reduced immune response after SARS-CoV-2 mRNA vaccination. In addition, higher SARS-CoV-2 antibody levels were observed in MS patients who received the Moderna vaccine compared with the Pfizer/BioNTech vaccine. Although 4 weeks after the second dose the Moderna vaccine generated higher antibody levels in MS patients receiving anti-CD20 therapies or fingolimod [1,2], it is unclear if this is of practical significance in anti-SARS-CoV-2 protective immunity. Disease-modifying therapies (DMTs) in MS patients are associated with a decreased immune response to antigens. A post-SARS-CoV-2 vaccination serological assessment was performed to examine the antibody response in MS patients treated with DMTs as compared with untreated patients. The current analysis of this prospective, multicentre cohort study assessed 1,339 MS patients (treated with a DMT, n=1,166; untreated, n=173) who r...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on